REDWOOD CITY, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today ...
BDC-4182 demonstrated compelling anti-tumor activity and an acceptable safety profile in preclinical studies BDC-4182 outperformed cytotoxic claudin 18.2 ADCs in syngeneic model Learnings from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results